Upstream of Gli, Vismodegib, a Smo inhibitor preventing activation of SHh target genes, has already been approved for basal cell carcinoma treatment, and is looking to expand its use to other cancers [55, 56]. The gene discussed is SMO; the disease is basal cell carcinoma.